REAL-Time Continuous Glucose Monitoring

When you use the optional REAL-Time Continuous Glucose Monitoring Kit with your MiniMed Paradigm® 522 or 722 Insulin Pump, you will have access to REAL-Time glucose readings, safety alarms, and glucose trend data around the clock.

The kit contains:

REAL-Time continuous glucose monitoring gives you important benefits that you can't get with fingerstick measurements alone.

Here's how it works as part of the MiniMed Paradigm® REAL-Time Insulin Pump and Continuous Glucose Monitoring System.

Easy to Wear, Easy to Use

MiniMed Paradigm<sup>®</sup> REAL-Time Insulin Pump Part of the #1 prescribed MiniMed Paradigm Brand of Insulin Pumps, the MiniMed Paradigm 522 or 722 Insulin PumpA is small so you can wear it almost anywhere – under your clothing in a leg pouch, thigh pouch, bra pouch, or on your belt like a cell phone. It delivers insulin through an infusion set that has a soft tube called a cannulaB that sits under your skin for up to three days after being inserted in one virtually painless step. You can disconnect from the insulin pump easily and quickly for activities such as bathing, swimming, or changing clothes.

REAL-Time Continuous Glucose Monitoring is made possible through a tiny glucose sensorC you wear for up to three days at a time. Like the cannula, it is easily inserted using an automatic insertion device provided with the system. Glucose sensor data is sent continuously to a MiniLink™ REAL-Time TransmitterD, a small lightweight device that attaches to the glucose sensor. The transmitter sends the glucose data to the insulin pump through advanced radio frequency (RF) wireless technology. (The glucose sensor, transmitter, and adhesive patch are all waterproof.)

REAL-Time Continuous Glucose Monitoring Lets You Enjoy REAL Control with REAL Confidence

A REAL-Time Readings help you take action sooner to improve control of your glucose levels and reduce the risk of long-term health complications. The MiniMed Paradigm REAL-Time System takes measurements continuously and monitors your glucose every minute and displays a five minute average to help you take the right action at the right time to improve control of your diabetes. Fingerstick measurements using a standard blood glucose meter are still required before making therapy adjustments, and to calibrate the system.1-3

B REAL-Time Alarms are designed to warn you of low and high glucose levels that fingersticks and A1C testing may miss.4 You can preset alarms to sound or vibrate. You can even customize the setting to just the right sensitivity for you.

C REAL-Time Trend Arrows point up or down to clearly show you the direction and rate of change in your glucose. Because even brief fluctuations can increase your risk of long-term problems, this information helps you reduce the risk of long-term complications such as eye, nerve, heart, and kidney disease.5

D REAL-Time Trend Graphs show you the effects of meals, exercise, insulin, and medication on your glucose levels. Additionally, you can upload historical data from the insulin pump to our FREE CareLink™ Personal software, where you can generate charts, graphs, and tables for your records or to share with your health care providers.6

Choose the Components You Need

The MiniMed Paradigm 522 or 722 Insulin Pump can be purchased and used on its own. The REAL-Time Continuous Glucose Monitoring Kit is sold separately as a cash pay item (not covered by most insurance plans).

Get started on the MiniMed Paradigm REAL-Time System.

Interested in Continuous Glucose Monitoring without an Insulin Pump?

Visit our Guardian® REAL-Time Continuous Glucose Monitoring System web page.

Paradigm, Sen-Serter, and Guardian are registered trademarks, and CareLink is a trademark of Medtronic MiniMed, Inc.

1
Bode BW, et al. Diabetes Research and Clin Practice.1999;46:183-90.
2
Kaufman FR, et al. Diabetes Care. 2001;24(12):2030.
3
Ludvigsson J, et al. Pediatrics. 2003;111(5 Pt 1):933-8.
4
Bode B, et al. Diabetes Technol Ther.2004;6(2):105-13.
5
DCCT Research Group. N Engl J Med. 1993;329(14):977-86.
6
EDIC study for kidney disease claim. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. NEJM 2005; 353(25): 2643-2653.